• Bingyan Gong, Nan Jiang, Guiming Yan, Siyuan Wang, Cuiyu Deng, Siqi Wei, and Yue Zhao.
• a School of Nursing , Tianjin Medical University , Tianjin , China.
• Curr Med Res Opin. 2016 Oct 1; 32 (10): 1701-1708.

PurposeTo identify the risk factors for severe acute esophagitis (AE) in lung cancer patients undergoing chemoradiotherapy (CRT).MethodsArticles from PubMed, EMBASE, and the Cochrane Library were searched in August 2015. Articles reporting studies of the predictors for severe AE in lung cancer patients after CRT were included. Study quality was assessed using a modified quality assessment tool that was designed previously for an observational study. The effects of studies were combined with the study quality score using a best-evidence synthesis model. Severe AE incidence was also performed using the Metafor package of R-2.11.1.ResultsA total of nine observational studies involving 1641 patients were included. The estimated incidence of severe AE was 14%. According to the best-evidence synthesis criteria, there were two strong-evidence risk factors for severe AE, which were the use of concurrent chemotherapy (CCT) and dose volume histogram (DVH). We also identified four limited-evidence risk factors.ConclusionsMore attention should be paid to the levels of patients' esophagus function. Although there is no conclusive evidence for severe AE in lung cancer patients after CRT, the above-mentioned factors provide evidence to guide clinicians as to which patients will have severe AE and to choose an optimal prophylactic strategy.

3 keywords...

hide…